The Effectiveness Of Crosslinking In Pediatric Keratoconus: Experience Of The Department
Published 2025 - 43rd Congress of the ESCRS
Reference: PO486 | Type: Free paper | DOI: 10.82333/0r8z-8225
Authors: Dan Reinstein* 1 , Timothy Archer 2 , Joseph Potter 2 , Ruchi Gupta 2 , Glenn Carp 2
1Centre Hospitalier National d’Ophtalmologie,Paris,France;London Vision Clinic,London,United Kingdom;Columbia University Medical Center,New York,United States, 2London Vision Clinic,London,United Kingdom
Purpose
Keratoconus (KC) is a progressive, degenerative, asymmetric, and bilateral disease of the cornea, characterized by corneal thinning and protrusion. It is classified as pediatric when it manifests before the age of 18. In young children, it is often severe and progresses rapidly, potentially leading to visual impairment. This highlights the importance of a stabilizing treatment, which should be proposed as a first-line option at the time of diagnosis. Crosslinking (CXL), which uses riboflavin, ultraviolet A (UVA), and oxygen to create covalent bonds between collagen fibrils, thereby increasing corneal stiffness, has proven effective in stabilizing this condition.
Setting
We report the department's experience through a retrospective study conducted in the pediatric ophthalmology department, involving patients who underwent CXL before the age of 18.
Methods
Results
Conclusions
Pediatric keratoconus tends to be aggressive and progressive in nature, making its management a significant challenge. Early and effective intervention, particularly through CXL, is crucial. Although CXL is not without risks, it allows long-term stabilization of the disease. Managing allergies, preventing eye rubbing, and ensuring clinical and pachymetric follow-ups are essential for maintaining positive outcomes and preventing therapeutic failure.